Cassava Sciences' stock plummeted over 80% as its Alzheimer's drug simufilam failed Phase III trials. The company halted all drug development, including an ongoing trial, due to disappointing results. Despite this, simufilam showed a favorable safety profile.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing